Enlivex Ltd. Form 6-K Summary
Business Context and Reporting Period
Enlivex Ltd., an Israeli company, filed this Form 6-K on March 23, 2026, for the month of March 2026. The filing reports a significant regulatory milestone regarding its clinical-stage immunotherapy, Allocetra®.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements.
Material Changes
On March 23, 2026, the U.S. Food and Drug Administration (FDA) cleared Enlivex's Investigational New Drug (IND) application for Allocetra®. This clearance permits the initiation of a global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial. The trial is designed to evaluate the efficacy and safety of intra-articular injections of Allocetra® in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA clearance and the planned commencement of the Phase 2b trial. The filing does not provide specific financial guidance, discuss general risks, or detail contingencies beyond the standard regulatory process for clinical trials.
Investor Verification Checklist
- Verify the specific protocol details and enrollment targets for the newly authorized Phase 2b trial.
- Confirm the timeline for the first patient enrollment and data readout.
- Review the company's cash runway to ensure sufficient liquidity to fund the global Phase 2b trial.
- Monitor subsequent filings for any updates on trial progress or additional regulatory requirements.